Tue, January 3, 2017
Fri, December 30, 2016
Thu, December 29, 2016
Wed, December 28, 2016
Tue, December 27, 2016
Mon, December 26, 2016
Fri, December 23, 2016
Thu, December 22, 2016
Wed, December 21, 2016
Tue, December 20, 2016
Mon, December 19, 2016
Fri, December 16, 2016
Thu, December 15, 2016
Wed, December 14, 2016
Tue, December 13, 2016

Paul Matteis Initiated (CDTX) at Buy and Held Target at $340 on, Dec 21st, 2016


  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. buy-and-held-target-at-340-on-dec-21st-2016.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Paul Matteis of Leerink Swann, Initiated "Cidara Therapeutics, Inc." (CDTX) at Buy and Held Target at $340 on, Dec 21st, 2016.

Paul has made no other calls on CDTX in the last 4 months.



There are 2 other peers that have a rating on CDTX. Out of the 2 peers that are also analyzing CDTX, 0 agree with Paul's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Paul


  • Ed Arce of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $500 on, Monday, December 19th, 2016
  • Stephen Brozak of "WBB Securities" Downgraded from Hold to Strong Sell on, Friday, September 23rd, 2016

Publication Contributing Sources